Huntington's disease (HD) is a neurodegenerative disorder involving progressive motor disturbances, cognitive decline, and desynchronized sleep-wake rhythms. Recent studies revealed that restoring normal sleep-wake cycles can improve cognitive function in HD mice, suggesting that some sleep/wake systems remain operational and thus represent potential therapeutic targets for HD. Hypothalamic neurons expressing orexins/hypocretins (orexin neurons) are fundamental orchestrators of arousal in mammals, but it is unclear whether orexin circuits operate normally in HD. Here we analyzed the electrophysiology, histology, and gene expression of orexin circuits in brain slices from R6/2 mice, a transgenic model of HD with a progressive neurological phenotype. We report that in R6/2 mice, the size of an electrically distinct subpopulation of orexin neurons is reduced, as is the number of orexin-immunopositive cells in some hypothalamic regions. R6/2 orexin cells display altered glutamatergic inputs, and have an abnormal circadian profile of activity, despite normal circadian rhythmicity of the suprachiasmatic nucleus (SCN), the "master clock" of the brain. Nevertheless, even at advanced stages of HD, intrinsic firing properties of orexin cells remain normal and suppressible by serotonin, noradrenaline, and glucose. Furthermore, histaminergic neurons (key cells required for the propagation of orexin-induced arousal) also display normal responses to orexin. Together, these data suggest that the orexin system remains functional and modifiable in HD mice, although its circadian activity profile is disrupted and no longer follows that of the SCN.
Introduction
Huntington's disease (HD) is an inherited progressive neurodegenerative disorder caused by a CAG repeat expansion mutation in the HTT gene causing a polyglutamine repeat expansion in the huntingtin protein (The Huntington's Disease Collaborative Study Group, 1993) . The exact function of huntingtin is unclear, although it has been implicated in many aspects of cellular function, including vesicle trafficking, axonal transport, signaling, transcriptional regulation, and mitochondrial dynamics (Cattaneo et al., 2005; Feany and La Spada, 2003; Reddy et al., 2009) . The presence of the HD mutation results in abnormal movement coordination, psychiatric disturbances, weight loss, and cognitive decline (Bates et al., 2002; Kumar et al., 2010) . The R6/2 transgenic mouse is one of the best characterized animal models of HD. It expresses a fragment of the HD gene and displays symptoms that recapitulate some of those seen in human HD patients (Carter et al., 1999; Lione et al., 1999; Mangiarini et al., 1996) . Recently, it was found that both R6/2 mouse and human HD patients display disrupted sleepwake rhythms that become increasingly fragmented with disease progression (Morton et al., 2005) . Because disrupted sleep is known to be deleterious to mental function, we proposed that restoration of normal sleep-wake rhythms might bring cognitive benefits to HD patients. Consistent with this idea, pharmacological or behavioral regularization of the sleep-wake cycle has been shown to improve cognitive function in R6/2 mice (Pallier et al., 2007; Pallier and Morton, 2009 ). However, a fundamental question relevant for informed design of such therapies remains unanswered: which components of the normal sleep-wake system are retained and which are lost in HD?
In mammals, the timing of sleep and wakefulness is profoundly affected by changes in the activity of the brain orexin/hypocretin system. Orexins/hypocretins are neurotransmitters made by a small group of hypothalamic neurons (de Lecea et al., 1998; Sakurai et al., 1998) . Orexin neurons provide major inputs to arousal centers, where orexins are released and act on two specific G-protein coupled receptors (Peyron et al., 1998; Sakurai et al., 1998) . Increased firing of orexin neurons stimulates wakefulness (Adamantidis et al., 2007) . This is of such critical importance for consolidating normal sleepwake rhythms that loss of orexin cells causes narcolepsy/cataplexy in dogs, mice, and humans (Hara et al., 2001; Thannickal et al., 2000) .
Studies of orexin levels in the extracellular space and/or of orexin peptide content of fixed hypothalamic tissue provided conflicting information as to whether orexin circuits function normally or 
